Suchergebnisse - Eva Muñoz‐Couselo

Treffer weiter einschränken
  1. 1
    Targeting FGFR pathway in breast cancer

    Targeting FGFR pathway in breast cancer von José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino, Fabricio Racca, Javier Cortés

    Veröffentlicht 2017
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    <em>NRAS</em>-mutant melanoma: current challenges and future prospect

    <em>NRAS</em>-mutant melanoma: current challenges and future prospect von Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? von Mar Riveiro‐Barciela, Eva Muñoz‐Couselo, Jesús Fernández‐Sojo, Nely Díaz‐Mejía, Rafael Parra-López, Marı́a Buti

    Veröffentlicht 2018
    Volltext Volltext
    Carta
    Zu den Favoriten
    Gespeichert in:
  4. 4
    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy von Adriana Sánchez‐Danés, Jean‐Christophe Larsimont, Mélanie Liagre, Eva Muñoz‐Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, V. del Mármol, Josep Tabernero, Cédric Blanpain

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 stud... von Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial von Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, Burak Gümüşçü, Ramona F. Swaby, Jean‐Jacques Grob

    Veröffentlicht 2021
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab von Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti... von Paolo A. Ascierto, Petri Bono, Shailender Bhatia, Ignacio Melero, Marta Nyakas, Inge Marie Svane, James Larkin, Carlos Gomez‐Roca, Dirk Schadendorf, R. Dummer, Aurélien Marabelle, Christoph Höeller, Mark Maurer, Christopher Harbison, Priyam Mitra, Satyendra Suryawanshi, Kent Thudium, Eva Muñoz‐Couselo

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-00... von Célèste Lebbé, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz‐Couselo, Caio Guilherme Pereira, Shahneen Sandhu, Ming Zhou, Brendan D. Curti, Nikhil I. Khushalani, Matthew Taylor, Alfonsus Van Den Eertwegh, Ute Hoch, Georgina Long AO, Yull Arriaga, Adi Diab, Helen Gogas

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of th... von Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz‐Couselo, Sung‐Bae Kim, Joohyuk Sohn, Seock‐Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer H. Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Rǎzvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid

    Veröffentlicht 2025
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) von Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, T. Ciuleanu, Eva Muñoz‐Couselo, A. Perfetti, Célèste Lebbé, Friedegund Meier, Brendan D. Curti, C. Rojas, Hwai‐I Yang, Ming Zhou, Shruthi Ravimohan, Mary Tagliaferri, N. Khushanlani

    Veröffentlicht 2022
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-... von Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, Frank J. Hsu, Harriet M. Kluger

    Veröffentlicht 2023
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury

    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury von Mar Riveiro‐Barciela, Ana Barreira‐Díaz, María‐Teresa Salcedo, Ana Callejo, Eva Muñoz‐Couselo, Patricia Iranzo, Carolina Ortiz, S. Cedrés, Nely Díaz‐Mejía, J. Cobo, Rafael Morales, Juan Aguilar‐Company, Esther Zamora, Mafalda Oliveira, María‐Teresa Sanz‐Martínez, L Viladomiu, Mónica Martínez‐Gallo, Enriqueta Felip, Marı́a Buti

    Veröffentlicht 2024
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Five latent factors underlie response to immunotherapy

    Five latent factors underlie response to immunotherapy von Joseph Usset, Axel K.M. Rosendahl Huber, Maria Andrianova, Eduard Batlle, Joan Carles, Edwin Cuppen, Elena Élez, Enriqueta Felip, Marina Gómez-Rey, Deborah Lo Giacco, Francisco Martínez-Jiménez, Eva Muñoz‐Couselo, Lillian L. Siu, Josep Tabernero, Ana Vivancos, Ferran Muiños, Abel González-Pérez, Núria López-Bigas

    Veröffentlicht 2024
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review

    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review von Peter Mohr, Felix Kiecker, Vincent Soriano, O. Dereure, Karmele Mujika, Philippe Saïag, Jochen Utikal, Rama Koneru, Caroline Robert, F. Perez Cuadros, Matías Chacón, Rodrigo U. Villarroel, Yana G. Najjar, Lisa A. Kottschade, Eva Muñoz‐Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu‐Ittu, Maurice Perrinjaquet, Jonathan S. Zager

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    2314P Quality and safety of research biopsies (RB) in oncology clinical trials

    2314P Quality and safety of research biopsies (RB) in oncology clinical trials von Paolo Nucíforo, Fiorella Ruíz‐Pace, J. Jiménez, Raquel Comas, R. Fasani, Cristina Viaplana, C. Sevillano, Pablo Martínez, X Serres i Créixams, C. Saura Manich, M.E. Elez Fernandez, Ana Oaknin, Irene Braña, Eva Muñoz‐Couselo, Teresa Macarulla, J. Carles Galceran, Josep Tabernero, Enriqueta Felip, Elena Garralda, Rodrigo Dienstmann

    Veröffentlicht 2023
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE</scp>‐119

    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE... von Javier Cortés, Eric P. Winer, O. N. Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K. Pruitt, Kenneth Emancipator

    Veröffentlicht 2024
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy... von Paolo A. Ascierto, Hao Tang, Sonia Dolfi, Marta Nyakas, Inge Marie Svane, Eva Muñoz‐Couselo, Jean‐Jacques Grob, Carlos Gomez‐Roca, Vanna Chiarion‐Sileni, Katriina Peltola, James Larkin, Ignacio Melero, Margaret K. Callahan, Reinhard Dummer, Patrick Djidel, Deepti Warad, Diane Reusser-Wolf, Evan J. Lipson, Charlie Garnett‐Benson

    Veröffentlicht 2025
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies von Azad Saei, Marta Palafox, Touati Benoukraf, Nishi Kumari, Patrick Jaynes, Prasanna Vasudevan Iyengar, Eva Muñoz‐Couselo, Paolo Nucíforo, Javier Cortés, Christopher Nötzel, Nesaretnam Barr Kumarakulasinghe, John Lalith Charles Richard, Zul Fazreen Bin Adam Isa, Brendan Pang, Marta Guzmán, Siqin Zhou, Henry Yang, Wai Leong Tam, Violeta Serra, Pieter J.A. Eichhorn

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics von Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa de Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep M. Piulats, Xavier Matías‐Guiu, Irene Braña, Eva Muñoz‐Couselo, Elena Garralda, Andreas Schlösser, Alena Gros

    Veröffentlicht 2023
    Volltext Volltext
    Carta
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: